Alcohol Use Disorder Medications: How Options Differ

Alcohol use disorder medications do different jobs: naltrexone can reduce the urge to drink, acamprosate helps maintain abstinence after drinking has stopped, and disulfiram discourages drinking through an alcohol reaction. Understanding these differences helps explain why a clinician considers your health, other medicines, and recovery goals before recommending an option.

There is no single medication that fits everyone, and none of these options replaces a separate assessment of alcohol withdrawal risk. The National Institute on Alcohol Abuse and Alcoholism treatment guide identifies these three medicines as approved U.S. treatments and explains that medication may be used with counseling and other support. This comparison focuses on each medicine’s purpose, major precautions, and place in ongoing treatment. It is general education, not a recommendation to start, stop, or select a prescription. You do not need to choose a medicine before seeking help.

What different jobs do alcohol use disorder medications do?

These medicines support changes in alcohol use through different approaches, rather than acting as interchangeable versions of one treatment. Within care that addresses substance use alongside mental health or broader outpatient treatment programs, understanding the medication’s specific job helps keep expectations clear. Medication information here does not establish that a particular prescription is available through Women’s Recovery.

Naltrexone addresses the urge to drink. Acamprosate supports avoiding a return to alcohol after a person has stopped drinking. Disulfiram creates an unpleasant reaction when alcohol is consumed, making it a deterrent rather than a medicine primarily aimed at easing cravings. These distinctions come from NIAAA’s descriptions of the three approved medications.

A treatment goal and a medication mechanism are related, but they are not the same thing. Wanting fewer cravings does not establish which prescription is safe. Wanting to remain alcohol-free does not mean disulfiram is automatically the best match. The clinician also needs to consider health conditions, other medicines, and the circumstances in which treatment will take place. NIAAA emphasizes that alcohol treatment is not one-size-fits-all.

This is a comparison of treatment purposes, not a ranking. A medicine can have a useful role and still be unsuitable for a particular person. Likewise, a precaution that rules out one option does not mean all medication treatment is ruled out. The individual assessment connects the treatment goal with the medication’s benefits, limits, and safety requirements.

How does naltrexone differ from acamprosate?

Naltrexone primarily helps reduce the urge to drink, while acamprosate helps maintain abstinence after drinking has stopped. NIAAA explains their different treatment roles, and MedlinePlus describes acamprosate as a medicine used with counseling and social support to help people avoid drinking again.

Naltrexone is an opioid antagonist. In plain language, it blocks opioid effects and can decrease alcohol craving. These are two distinct actions of the same medicine. Its opioid-blocking action creates additional safety considerations even when alcohol, rather than opioids, is the reason for treatment. MedlinePlus describes naltrexone’s action and precautions.

The opioid-blocking action is especially important when someone uses prescription pain medicine, certain cough or diarrhea medicines containing opioids, or medication for opioid use disorder. Recent opioid exposure can make starting naltrexone unsafe because it can cause or worsen withdrawal. Attempts to overcome its opioid blockade can cause serious injury or death. These are reasons for a prescriber-led review, not reasons to stop another prescription independently. MedlinePlus provides the opioid-related warnings.

Acamprosate works differently. MedlinePlus explains that it helps balance chemicals in the brain and is used after a person has stopped drinking. Its treatment job is to support continuing without alcohol. It does not work by making alcohol exposure unpleasant, and it does not produce the reaction associated with disulfiram. The acamprosate medication guide explains both points.

This difference matters when interpreting symptoms. A continuing urge to drink, difficulty maintaining abstinence, and a medication side effect are not identical problems. A clinical review needs to distinguish them rather than treating every difficult day as proof that a prescription is ineffective. Both medication guides place these medicines within an ongoing treatment plan that includes counseling and support.

Naltrexone is available in oral and injectable forms, while acamprosate is an oral medicine. Form can affect the practical treatment discussion, but it does not establish which option is clinically appropriate. NIAAA describes these available forms; this article does not establish access to either form through Women’s Recovery. See NIAAA’s medication overview.

How is disulfiram different from medicines that address cravings?

Disulfiram discourages drinking by causing an unpleasant reaction when alcohol is consumed. That is a different treatment approach from reducing the urge to drink or helping maintain abstinence through acamprosate. NIAAA describes disulfiram as an alcohol deterrent, while MedlinePlus details its precautions and possible alcohol reaction.

The reaction can include flushing, headache, nausea, vomiting, chest pain, confusion, and breathing difficulty. It should not be described as merely an unpleasant reminder or a harmless consequence. Because the possible effects include serious symptoms, taking disulfiram requires a clear understanding of alcohol exposure and the prescriber’s safety instructions. Chest pain, trouble breathing, collapse, or other severe symptoms require immediate emergency help through 911. MedlinePlus describes the reaction and emergency warning signs.

Alcohol exposure is broader than a glass of wine or a mixed drink. The medication guide identifies alcohol-containing medicines, foods, beverages, and some household or personal-care products as concerns. Product labels and professional guidance therefore matter. An article cannot establish that a particular cough medicine, sauce, mouth product, or skin product is safe for someone taking disulfiram. A pharmacist or prescriber should resolve that uncertainty. MedlinePlus explains these exposure precautions.

The alcohol-reaction risk does not necessarily end when the prescription is stopped. MedlinePlus warns that a reaction can occur after discontinuation. That is why stopping the medicine must not be treated as immediate permission to drink. The prescriber’s instructions should govern this part of the plan; a general comparison cannot supply an individual safety timeline.

Consent is essential. Disulfiram must never be given without the person’s full knowledge or while she is intoxicated, according to the medication’s prominent warning. A concerned family member cannot make it safe by hiding it in food or describing it as a supplement. Medication treatment is not a punishment or a way for another person to control drinking.

Disulfiram also does not make the emotional or social reasons for drinking disappear. Its deterrent role and the work of counseling address different parts of treatment. A plan still needs to consider stress, alcohol-related routines, relationships, and support, which NIAAA identifies as important areas of alcohol treatment.

Which health and medication factors shape prescribing decisions?

Prescribing depends on the whole health picture, not just which medicine sounds appealing. Physical health, other prescriptions, pregnancy or breastfeeding, and mental health concerns all matter. These issues belong within coordinated substance use and mental health care and, when appropriate, psychiatric care within outpatient treatment. Those care connections do not establish availability of a particular alcohol medicine.

The major considerations differ across the three options. The following are prescribing issues, not a checklist for deciding on treatment yourself:

• Opioid exposure and pain treatment: Naltrexone blocks opioid effects and can cause or worsen opioid withdrawal. Current or recent opioid use, including prescribed medicines, needs clinician review. Naltrexone precautions.
• Kidney health: Kidney disease is an important part of the acamprosate prescribing review. Kidney history also appears in the precautions for naltrexone and disulfiram. The implications depend on the medicine and the person.
• Liver and heart history: Liver disease needs review with naltrexone and disulfiram. MedlinePlus specifically warns that severe heart disease may make disulfiram inappropriate. Naltrexone health considerations and disulfiram health considerations.
• Other medicines and supplements: Prescription medicines, nonprescription products, vitamins, and herbal products can affect prescribing or monitoring decisions. A familiar product should not be assumed compatible. Disulfiram interaction precautions.
• Pregnancy, breastfeeding, and mental health: These circumstances require individual consideration. The medication guides identify pregnancy or breastfeeding and relevant mental health history as information for the prescriber. Naltrexone and acamprosate medication information.

Side effects are another part of the comparison. Naltrexone can cause nausea, headache, dizziness, and sleep changes. Acamprosate can cause diarrhea, stomach upset, and dizziness. Disulfiram can cause drowsiness, tiredness, headache, or an unusual taste. These examples are not complete lists, and overlapping symptoms do not identify the cause. The individual guides describe naltrexone side effects, acamprosate side effects, and disulfiram side effects.

New yellowing of the skin or eyes, dark urine, or marked unusual tiredness should receive prompt medical attention, particularly during naltrexone or disulfiram treatment. Their medication guides identify possible serious liver-related symptoms. New depression or suicidal thinking also needs prompt attention and must not be dismissed as an expected part of recovery. See the naltrexone safety information, disulfiram safety information, and acamprosate mental health precautions.

Why is withdrawal management a separate medical decision?

Withdrawal management addresses the immediate medical risks of reducing or stopping alcohol; an ongoing alcohol medication plan addresses a different treatment need. Women’s Recovery’s PHP, IOP, and outpatient programs are not onsite detox services. Understanding when emergency care is needed instead of outpatient treatment helps keep an urgent medical problem separate from a routine treatment discussion.

After prolonged heavy drinking, suddenly stopping can cause potentially life-threatening withdrawal. NIAAA lists symptoms including nausea, a rapid heart rate, seizures, and other problems, and recommends medical help to plan a safe recovery. A clinician needs to assess withdrawal risk and the appropriate care setting rather than relying on a person’s determination or a medicine intended for ongoing alcohol treatment. NIAAA explains alcohol withdrawal risk.

Naltrexone does not prevent or relieve alcohol withdrawal symptoms, according to MedlinePlus. Likewise, the treatment roles described for acamprosate and disulfiram should not be mistaken for instructions to manage acute withdrawal. Knowing a medication’s name is not enough to establish that stopping alcohol without medical oversight is safe.

The distinction also works in the other direction: completing withdrawal management does not complete alcohol use disorder treatment. The American Society of Addiction Medicine guideline states that withdrawal management alone is not effective treatment for alcohol use disorder. Ongoing treatment addresses the needs that remain after the immediate withdrawal risk has been managed.

How can medication and behavioral treatment work together?

Medication and behavioral treatment can address different parts of the same alcohol problem. A prescription may support a change in alcohol use, while therapy develops ways to manage situations and patterns linked to drinking. Women’s Recovery describes substance use care alongside mental health and trauma within its outpatient programs. This is not a claim that any specific medication or prescribing arrangement is available.

NIAAA describes behavioral treatments as professionally led approaches that help change drinking behavior. Their shared features can include developing coping skills, building social support, setting reachable goals, and managing triggers. Medication does not make those treatment tasks unnecessary, and needing medication does not mean a woman has failed to use her skills. NIAAA explains behavioral treatment and medication options.

For example, a medicine aimed at reducing the urge to drink and therapy focused on a recurring after-work drinking pattern have different jobs. One addresses the urge; the other can examine the stress, expectations, and repeated behaviors surrounding it. This is an illustration of complementary treatment roles, not a prediction about how a particular person will respond.

• Recognizing cues: Behavioral treatment can help identify feelings, people, places, or situations connected with drinking.
• Developing alternatives: Therapy can build ways to manage stress and everyday situations without returning to the same alcohol-related response.
• Strengthening support: Treatment can include building supportive relationships and, where appropriate, family or couples work.
• Maintaining engagement: Ongoing care allows the treatment plan to be reconsidered as needs and circumstances change.

These are treatment functions described in NIAAA’s guide to alcohol treatment, not additional assignments a person must finish before reaching out. They also explain why a useful treatment plan is broader than tracking whether a prescription was taken.

Mental health needs deserve attention alongside alcohol use. NIAAA notes that depression, anxiety, trauma-related conditions, and sleep disorders can co-occur with alcohol use disorder and recommends addressing accompanying health concerns. Treating alcohol use does not automatically resolve every mood, trauma, or sleep symptom. NIAAA discusses co-occurring mental health concerns.

Peer support can add connection, but it serves a different role from prescribing and clinical treatment. NIAAA describes mutual-support groups as a potentially valuable added layer alongside professionally led care. A peer’s experience with a medicine can be meaningful without establishing that the same prescription is appropriate for someone else.

How should an ongoing medication plan be reviewed?

An ongoing medication review should consider benefit, side effects, safety, and how the prescription fits the rest of treatment. It should not reduce recovery to a single difficult day or a yes-or-no judgment about effort. Broader treatment plan reviews and attention to changing needs during care provide context, while medication decisions remain with the prescribing professional.

The medicine’s intended purpose helps define what the review means. For naltrexone, the discussion may include the urge to drink and the alcohol-use pattern. For acamprosate, maintaining abstinence is central. For disulfiram, the deterrent role and alcohol-exposure precautions remain important. These are distinct treatment purposes described by NIAAA, not guaranteed outcomes or a self-scoring system.

A return to drinking warrants clinical attention, not automatic self-blame or an unsupervised medication change. NIAAA explains that setbacks can occur and that a treatment provider can help adjust the plan. The medical meaning differs by medicine, especially because drinking during disulfiram treatment can cause a serious reaction. See NIAAA’s discussion of ongoing treatment and disulfiram’s alcohol warning.

New prescriptions, planned surgery or dental treatment, pregnancy, and changes in physical or mental health can also alter the safety discussion. In particular, clinicians providing medical or dental care need to know about naltrexone because it blocks opioid effects. Medication changes should be guided by the prescriber or pharmacist rather than by a general article. MedlinePlus explains these naltrexone precautions.

The central comparison remains straightforward: naltrexone can reduce the urge to drink, acamprosate supports remaining alcohol-free after stopping, and disulfiram deters drinking through an alcohol reaction. The appropriate choice depends on an individual medical assessment, not on which option sounds strongest.

For outpatient mental health, trauma, and substance use care in Denver, CO, explore Women’s Recovery’s programs or contact the team at 833.754.0554. Women’s Recovery does not provide onsite detox, residential, or inpatient services. A program conversation does not require choosing a medication first.

Editorial content by Tim Francis.

Frequently asked questions